Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis.

IF 3 3区医学 Q2 ONCOLOGY

Breast Cancer Research and Treatment Pub Date : 2025-01-09 DOI:10.1007/s10549-024-07606-1

Talar Ozler, Rusen Cosar, Necdet Sut, Dilek Nurlu, Şule Parlar, Sinan Ateş, Mert Hacı Dertli, Yusuf Kavuzlu, Sekip Kavukcu, Mert Chousein, Gokay Yıldız, Nermin Tunçbilek, Muhammet Bekir Hacıoglu, Ebru Tastekin, Sernaz Topaloğlu

{"title":"Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis.","authors":"Talar Ozler, Rusen Cosar, Necdet Sut, Dilek Nurlu, Şule Parlar, Sinan Ateş, Mert Hacı Dertli, Yusuf Kavuzlu, Sekip Kavukcu, Mert Chousein, Gokay Yıldız, Nermin Tunçbilek, Muhammet Bekir Hacıoglu, Ebru Tastekin, Sernaz Topaloğlu","doi":"10.1007/s10549-024-07606-1","DOIUrl":null,"url":null,"abstract":"Purpose: The characteristics of patients with bilateral and unilateral breast cancer at the time of diagnosis or during follow-up have been compared, focusing on the differences in disease-free survival and overall survival between these groups.Methods: A total of 1,947 patients diagnosed with invasive carcinoma were included in the study. 1876 (96.4%) of our patients had unilateral and 71 (3.6%) had bilateral breast cancer. Among the bilateral breast cancer patients n = 47 were metachronous, while n = 24 were synchronous.Results: SBBC, which had the lowest OS duration, showed a statistically significant difference compared to MBCC, similar to that observed in unilateral breast cancer (p = 0.027).Conclusion: The fact that SBBC has the lowest survival rate despite more aggressive treatments should be considered a poor prognostic factor for survival on its own.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07606-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The characteristics of patients with bilateral and unilateral breast cancer at the time of diagnosis or during follow-up have been compared, focusing on the differences in disease-free survival and overall survival between these groups.

Methods: A total of 1,947 patients diagnosed with invasive carcinoma were included in the study. 1876 (96.4%) of our patients had unilateral and 71 (3.6%) had bilateral breast cancer. Among the bilateral breast cancer patients n = 47 were metachronous, while n = 24 were synchronous.

Results: SBBC, which had the lowest OS duration, showed a statistically significant difference compared to MBCC, similar to that observed in unilateral breast cancer (p = 0.027).

Conclusion: The fact that SBBC has the lowest survival rate despite more aggressive treatments should be considered a poor prognostic factor for survival on its own.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.